Buffington Mohr McNeal’s Teva Pharmaceuticals TEVA Stock Holding History

Buffington Mohr McNeal’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-17,878	Closed	-$648K	–	131
2016 Q4	$648K	Sell	17,878 -455	-2%	-$18.2K	0.25%	70
2016 Q3	$843K	Sell	18,333 -375	-2%	-$19.6K	0.35%	57
2016 Q2	$940K	Sell	18,708 -80	-0.4%	-$4.26K	0.41%	54
2016 Q1	$1M	Sell	18,788 -230	-1%	-$13.5K	0.44%	49
2015 Q4	$1.25M	Buy	19,018 +2,750	+17%	+$170K	0.67%	33
2015 Q3	$918K	Sell	16,268 -70	-0.4%	-$4.54K	0.6%	32
2015 Q2	$965K	Buy	16,338 +718	+5%	+$44.3K	0.54%	37
2015 Q1	$973K	Buy	15,620 +9,605	+160%	+$558K	0.54%	37
2014 Q4	$346K	Buy	6,015 +2,265	+60%	+$126K	0.2%	50
2014 Q3	$202K	Buy	+3,750	New	+$199K	0.11%	58

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Buffington Mohr McNeal's TEVA Position: Q1 2017 in Review

Buffington Mohr McNeal sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 17,878 shares — an estimated $648K sold.

Buffington Mohr McNeal first reported a position in TEVA in Q3 2014 and held it in 10 quarters. The position peaked at $1.25M in Q4 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Buffington Mohr McNeal reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Buffington Mohr McNeal sold 17,878 Teva Pharmaceuticals shares in Q1 2017, an estimated $648K.
Buffington Mohr McNeal first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 10 quarters.
Buffington Mohr McNeal's Teva Pharmaceuticals position peaked at $1.25M in Q4 2015.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Buffington Mohr McNeal's 13F filing for Q1 2017, filed 3 May 2017.